Biotechnology

Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development

Recursion Pharmaceuticals partners with MIT for Boltz-2, an AI model predicting binding affinity at unprecedented speed and accuracy.

Taysha Gene Therapies Stock (TSHA): Innovative Gene Therapy Focus

Taysha Gene Therapies (NASDAQ: TSHA) is gaining investor attention with TSHA-102, its lead Rett syndrome gene therapy. Learn why this biotech stock is a rising contender in the CNS space.

Cidara Therapeutics Stock (CDTX): A Notable Contender in Antivirals

Cidara Therapeutics aims to innovate antivirals with CD388, targeting flu prevention. Positive trial results may boost stock.

Vigil Neuroscience Stock (VIGL): Buyout Boosts Valuation

Vigil Neuroscience's stock soared after Sanofi agreed to buy it for $8.00 per share, tied to the potential success of its Alzheimer’s drug VG-3927.

Capricor Stock (CAPR) Launch Hype Builds on Potential Breakthrough Therapy

Capricor Therapeutics (CAPR) stock climbs as FDA decision nears for its Duchenne therapy, with peak sales forecast at $3.3B by 2038.

Geron Corp Stock (GERN): Demand Recovery on the Rise

Geron Corporation's stock (GERN) is gaining attention due to its promising biotech advancements, particularly with its lead drug, Rytelo.

CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials

CytomX Therapeutics stock surges 280% on promising cancer data and a $93.4 million stock offering, bolstering its financial future.

Iovance Biotherapeutics Stock (IOVA): Navigating Turbulent Times

Iovance shares plunged on weak Q1 results and production issues, then bounced 10% as investors reassessed. Legal risks and volatility remain high.

Northwest Biotherapeutics Stock (NWBO) Faces Challenges Ahead

Northwest Biotherapeutics (NWBO stock) bounces in pre-market trading after a steep drop, as investors reassess its high-stakes outlook amid mounting volatility.

Healthcare Disruptors: AI, Telehealth and Cost Savings

UnitedHealth, Elevance Health, Cigna, and Medicus Pharma are driving AI, telehealth, and value-based care to transform patient outcomes and cost efficiency.

Healthcare Climbs as Tech Stumbles in 2025 Shift

Not all corners of the market are moving in the same direction this year. 2025 has already delivered a few surprises for sector-focused investors.

While Big Pharma Stalls, One Small-Cap Breaks Out

The market’s focus is narrow, but step outside the spotlight, and you’ll find where real momentum is building.

23andMe (NASDAQ: ME): Bankruptcy Filing and Strategic Sale Process

23andMe has filed for Chapter 11 to maximize business value while facing a steep decline, leadership change, and investment risks surrounding genetics.

3 US Healthcare Stocks That Might Be Undervalued 2025

Healthcare is showing strength in a shaky market—discover which overlooked U.S. stocks could potentially offer upside as the sector regains investor attention.

Medicus Pharma Share Price: MDCX Stock Closed Up 15.35%

Medicus Pharma Share Price Soars: Medicus Pharma closed yesterday at $3.4950, up 15.35% from the previous close of $3.03. Find out all you need to know.